linkedin

Press Releases

Samsung BIO Insight

CPHI Worldwide 2022 | Samsung Biologics introduces its client-centric slogan – ‘Accelerating Excellence’

SamsungBIologics_CPHI_2022_Thumbnail.jpg
 

Samsung Biologics participated in CPHI Worldwide 2022 held in Frankfurt, Germany, from Nov. 1 to 3, promoting its newly launched slogan ‘Accelerating Excellence’ and CDMO business capabilities in addition to discussing partnership opportunities with prospective clients.  

 

 

Accelerating Excellence, Samsung Biologics’ core strength

 

At CPHI, where more than 40,000 healthcare professionals representing over 2,500 biopharmaceutical companies from 170 countries gathered, Samsung Biologics showcased its business milestones and growth in one of the largest booths at the global conference, and hosted various events including speaking sessions and an exclusive networking session to promote Plant 4 and commitment to quality and speed.

 

SamsungBIologics_CPHI2022_1.jpg
SamsungBIologics_CPHI2022_2.jpg
 

“At the exclusive luncheon event, client questions mainly centered around the growing manufacturing capacity at Samsung Biologics, as well as the new mRNA business. We emphasized our end-to-end service capability through introducing the newly launched CDO platform services – S-DUAL™ bispecific antibody platform, and DEVELOPICK™ developability assessment platform,” said Grace Chung from Global Sales at Samsung Biologics.

 

On the first day of the conference, Kevin Sharp, VP of Global Sales at Samsung Biologics, presented under the topic – What are the key considerations in choosing the right CDMO partner?

 

SamsungBIologics_CPHI2022_3.jpg
 

“The demand for biomedicines is forecasted to exceed supply by 2026,” he said. “As a lot of investment and time are required to mass-produce biomedicines on time, a strategic partnership with an industry-proven CDMO like Samsung Biologics would help global biotech companies to run businesses more efficiently and put more concentrated efforts into developing new, innovative medicines.” While emphasizing the company’s overall capability differentiated from others, he also stressed that Samsung Biologics has built the world’s largest biomedicine production facility and earned more than 160 global regulatory approvals at speed with reliability across every business platform.

 

On day two, James Choi, EVP and Chief Information and Marketing Officer at Samsung Biologics, laid out a ESG initiative at Samsung Biologics in a session titled – Partnering with CDMOs for a Sustainable Future. “The biopharmaceutical industry is responsible of about 4 to 5% of global greenhouse gas emissions released into the air, and about half of those emissions come from supply chain operations,” said Choi, emphasizing why a strategic partnership with a sustainable CDMO has become imperative for a biotech company to establish a sustainable business model.

 

SamsungBIologics_CPHI2022_4.jpg
 

 

Client-tailored contents and events


Meanwhile, Samsung Biologics’ vibrant booth grabbed conference-goers’ attention with a large display allowing visitors to watch and easily learn the company’s innovative work and accomplishment at a glance.

The company’s capabilities in CMO, CDO and ESG management were each displayed on individual wall graphics, and vigorous marketing activities, including a digital surveys, happy hour and lucky draw events, were carried out throughout the conference.

 

SamsungBIologics_CPHI2022_5.jpg
SamsungBIologics_CPHI2022_6.jpg

SamsungBIologics_CPHI2022_7.jpg
SamsungBIologics_CPHI2022_8.jpg
SamsungBIologics_CPHI2022_9.jpg
SamsungBIologics_CPHI2022_10.jpg
SamsungBIologics_CPHI2022_11.jpg
 

 

Samsung Biologics’ aim to create a sustainable future


“Sustainability is definitely a rising trend within the biopharmaceutical industry,” said a CPHI conference organizer. “That’s why CPHI Worldwide 2022 created a sustainability theater for the first time in the conference history.” The organizer also added that the CPHI conference is looking to support the industry to responsibly advance for a greener future by sharing model episodes and providing networking opportunities for global companies to build a sustainable partnership.

 

In addition to Sustainability, Digitalization was also featured as a keyword at the conference this year.

CPHI Worldwide 2022 closed on a very high note this year, with great turnouts from the growing industry. As a leading CDMO, Samsung Biologics will continue to tread on to build a healthier, sustainable future, accelerating excellence.

 

SamsungBIologics_CPHI2022_12.jpg

SamsungBIologics_CPHI2022_13.jpg
 

 

 

Related Contents

 

Samsung BIO Insight Samsung Biologics’ Super Plant 4, How the world’s largest biomanufacturing plant will drive clients’ success

Samsung BIO Insight Unlocking the Possibilities to the Future of Biopharma | 2022 BIO International Convention

Samsung BIO Insight BioProcess International 2022 | Samsung Biologics unveils new development platforms to offer differentiated services

 

SamsungBIologics_CPHI_2022_Thumbnail.jpg
 

Samsung Biologics participated in CPHI Worldwide 2022 held in Frankfurt, Germany, from Nov. 1 to 3, promoting its newly launched slogan ‘Accelerating Excellence’ and CDMO business capabilities in addition to discussing partnership opportunities with prospective clients.  

 

 

Accelerating Excellence, Samsung Biologics’ core strength

 

At CPHI, where more than 40,000 healthcare professionals representing over 2,500 biopharmaceutical companies from 170 countries gathered, Samsung Biologics showcased its business milestones and growth in one of the largest booths at the global conference, and hosted various events including speaking sessions and an exclusive networking session to promote Plant 4 and commitment to quality and speed.

 

SamsungBIologics_CPHI2022_1.jpg
SamsungBIologics_CPHI2022_2.jpg
 

“At the exclusive luncheon event, client questions mainly centered around the growing manufacturing capacity at Samsung Biologics, as well as the new mRNA business. We emphasized our end-to-end service capability through introducing the newly launched CDO platform services – S-DUAL™ bispecific antibody platform, and DEVELOPICK™developability assessment platform,” said Grace Chung from Global Sales at Samsung Biologics.

 

On the first day of the conference, Kevin Sharp, VP of Global Sales at Samsung Biologics, presented under the topic – What are the key considerations in choosing the right CDMO partner?

 

SamsungBIologics_CPHI2022_3.jpg
 

“The demand for biomedicines is forecasted to exceed supply by 2026,” he said. “As a lot of investment and time are required to mass-produce biomedicines on time, a strategic partnership with an industry-proven CDMO like Samsung Biologics would help global biotech companies to run businesses more efficiently and put more concentrated efforts into developing new, innovative medicines.” While emphasizing the company’s overall capability differentiated from others, he also stressed that Samsung Biologics has built the world’s largest biomedicine production facility and earned more than 160 global regulatory approvals at speed with reliability across every business platform.

 

On day two, James Choi, EVP and Chief Information and Marketing Officer at Samsung Biologics, laid out a ESG initiative at Samsung Biologics in a session titled – Partnering with CDMOs for a Sustainable Future. “The biopharmaceutical industry is responsible of about 4 to 5% of global greenhouse gas emissions released into the air, and about half of those emissions come from supply chain operations,” said Choi, emphasizing why a strategic partnership with a sustainable CDMO has become imperative for a biotech company to establish a sustainable business model.

 

SamsungBIologics_CPHI2022_4.jpg
 

 

Client-tailored contents and events


Meanwhile, Samsung Biologics’ vibrant booth grabbed conference-goers’ attention with a large display allowing visitors to watch and easily learn the company’s innovative work and accomplishment at a glance.

The company’s capabilities in CMO, CDO and ESG management were each displayed on individual wall graphics, and vigorous marketing activities, including a digital surveys, happy hour and lucky draw events, were carried out throughout the conference.

 

SamsungBIologics_CPHI2022_5.jpg
SamsungBIologics_CPHI2022_6.jpg

SamsungBIologics_CPHI2022_7.jpg
SamsungBIologics_CPHI2022_8.jpg
SamsungBIologics_CPHI2022_9.jpg
SamsungBIologics_CPHI2022_10.jpg
SamsungBIologics_CPHI2022_11.jpg
 

 

Samsung Biologics’ aim to create a sustainable future


“Sustainability is definitely a rising trend within the biopharmaceutical industry,” said a CPHI conference organizer. “That’s why CPHI Worldwide 2022 created a sustainability theater for the first time in the conference history.” The organizer also added that the CPHI conference is looking to support the industry to responsibly advance for a greener future by sharing model episodes and providing networking opportunities for global companies to build a sustainable partnership.

 

In addition to Sustainability, Digitalization was also featured as a keyword at the conference this year.

CPHI Worldwide 2022 closed on a very high note this year, with great turnouts from the growing industry. As a leading CDMO, Samsung Biologics will continue to tread on to build a healthier, sustainable future, accelerating excellence.

 

SamsungBIologics_CPHI2022_12.jpg

SamsungBIologics_CPHI2022_13.jpg
 

 

 

Related Contents

 

Samsung BIO Insight Samsung Biologics’ Super Plant 4, How the world’s largest biomanufacturing plant will drive clients’ success

Samsung BIO Insight Unlocking the Possibilities to the Future of Biopharma | 2022 BIO International Convention

Samsung BIO Insight BioProcess International 2022 | Samsung Biologics unveils new development platforms to offer differentiated services

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved